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Critical Role for Interferon Regulatory Factor 3 (IRF-3) and IRF-7 in
Type I Interferon-Mediated Control of Murine Norovirus Replication
Larissa B. Thackray,a Erning Duan,a Helen M. Lazear,b Amal Kambal,a Robert D. Schreiber,a Michael S. Diamond,a,b,c and
Herbert W. Virgina,c
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USAa; Department of Medicine, Washington University School
of Medicine, St. Louis, Missouri, USAb; and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USAc
Human noroviruses (HuNoV) are the major cause of epidemic, nonbacterial gastroenteritis in the world. The short course of
HuNoV-induced symptoms has implicated innate immunity in control of norovirus (NoV) infection. Studies using murine no-
rovirus (MNV) confirm the importance of innate immune responses during NoV infection. Type I alpha and beta interferons
(IFN-/) limit HuNoV replicon function, restrict MNV replication in cultured cells, and control MNV replication in vivo.
Therefore, the cell types and transcription factors involved in antiviral immune responses and IFN-/-mediated control of
NoV infection are important to define. We usedmice with floxed alleles of the IFNAR1 chain of the IFN-/ receptor to identify
cells expressing lysozymeM or CD11c as cells that respond to IFN-/ to restrict MNV replication in vivo. Furthermore, we
show that the transcription factors IRF-3 and IRF-7 work in concert to initiate unique and overlapping antiviral responses to
restrict MNV replication in vivo. IRF-3 and IRF-7 restrict MNV replication in both cultured macrophages and dendritic cells, are
required for induction of IFN-/ in macrophages but not dendritic cells, and are dispensable for the antiviral effects of IFN-
/ that blockMNV replication. These studies suggest that expression of the IFN-/ receptor onmacrophages/neutrophils and
dendritic cells, as well as of IRF-3 and IRF-7, is critical for innate immune responses to NoV infection.
Viruses within the genus Norovirus of the family Caliciviridaeare the major etiologic agents of epidemic, nonbacterial gas-
troenteritis, causing 90% of viral gastroenteritis and 50% of
all-cause outbreaks worldwide (22, 52). Human noroviruses
(HuNoV) are also an important cause of sporadic gastroenteritis
(53). HuNoV infection has been associated with necrotizing en-
terocolitis in infants and postinfectious irritable bowel syndrome
in adults (44, 67, 71). Murine noroviruses (MNVs) are enteric
viruses that share many molecular and biological properties with
HuNoV (reviewed in references 25 and 77). MNV infection has
been reported to trigger Crohn’s disease-like intestinal pathology
(7, 8) and atherosclerosis progression (51) and to exacerbate en-
teric bacterial infection (32, 37). The capacity of MNVs to grow in
culture and infect mice permits the dissection of immune re-
sponses during NoV infection in vitro and in vivo.
The short course of HuNoV disease (often only 2 to 3 days)
suggests that innate immune responses play a key role in con-
trol of HuNoV infection. Elevated interferon (IFN) levels are
observed in ex vivo-stimulated peripheral blood mononuclear
cells and in serum from human volunteers and gnotobiotic pigs
inoculated with HuNoV (39, 63). Studies using MNV provide
strong support for the role of innate immune responses, in-
cluding both type I and type II IFN (IFN-/ and IFN-), in
controlling norovirus (NoV) replication both in vivo and
in vitro (13, 28, 31, 32, 49, 76). The relevance of these observa-
tions is supported by studies showing a reduction of HuNoV
RNA and protein expression in cells expressing replicons after
IFN treatment (11, 12). IFN-/ responses during NoV infec-
tion are likely initiated by the pattern recognition receptors
melanoma differentiation-associated protein 5 (MDA-5) and
Toll-like receptor 3 (TLR-3), since mice lacking MDA-5 or
TLR-3 have elevated MNV replication compared to wild-type
mice (46). However, the molecular pathways downstream of
virus recognition which induce IFN-/ responses during
NoV infection are unknown. In addition, the role of specific
cells and tissues in mediating IFN-/ responses during NoV
infection has not been defined.
Despite the importance of noroviruses with regard to public
health, no drug or vaccine is currently available to treat or prevent
HuNoV infection. The potential for long-term homologous pro-
tection against NoV infection has been shown by previous studies
using the murine and chimpanzee model systems (5, 9). Impor-
tantly, a recent study showed that it is possible to vaccinate against
homologous challenge with a HuNoV strain, providing support
for the idea that vaccination of the population may be possible (2,
21). Several recent studies show that IFN-/ is also important for
generating effective antiviral CD8 T-cell responses (41, 54, 70,
72–74). Therefore, it is likely that IFN-/ responses participate
in both innate and adaptive immune responses to NoV infection.
IFN regulatory factor 3 (IRF-3) and IRF-7 are key mediators of
transcriptional responses upon virus infection and are therefore
likely candidates for initiating IFN-/ responses to NoV infection.
IRF-3 is constitutively expressed in most cell types and activated by
phosphorylation upon virus infection (60, 78). IRF-7 expression is
induced by IFN in most cell types; IRF-7 is constitutively expressed in
plasmacytoid dendritic cells and also activated by phosphorylation
upon virus infection (4, 29, 56). Mice lacking IRF-3 (IRF-3/) are
susceptible to lethal infection with encephalomyocarditis virus
(EMCV) and West Nile virus (WNV), but their systemic IFN-/
response upon virus infection remains relatively intact (17, 57). In
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contrast, the systemic IFN- response upon virus infection is de-
creased in mice lacking IRF-7 (IRF-7/), and these mice are more
susceptible than IRF-3/mice to infection with EMCV, WNV, and
herpes simplex virus-1 (18, 26).
Here, we used mice with a targeted knockout (Ifnar1tm1Agt) or
floxed allele (Ifnar1tm1Uka) of the IFNAR1 chain of the IFN-/
receptor (IFN-/R) to show that signaling through the IFN-
/R and cells expressing lysozyme M (macrophages/neutro-
phils) or CD11c (dendritic cells) restrict MNV replication in vivo.
Further, we found that IRF-3 and IRF-7 are key initiators of anti-
viral immune responses that restrict MNV replication in multiple
tissues and in primary macrophages and dendritic cells. Lastly, we
found that IRF-3 and IRF-7 are essential for induction of IFN-/
in primary macrophages, but not primary dendritic cells, and are
not required for IFN-/-dependent generation of an antiviral
state. These data suggest a key role for macrophages/neutrophils,
dendritic cells, IRF-3, and IRF-7 in innate immunity to NoV in-
fection.
MATERIALS AND METHODS
Mice and infections.The original Ifnar1tm1Uka (herein called IFN-/Rf/f),
Ifnar1tm1Agt (herein called IFN-/R/), and IRF3/ and IRF7/
mice were generously provided by Ulrich Kalinke (Paul-Ehrlich-Institut,
Langen, Germany), Michel Aguet (Swiss Institute for Experimental Can-
cer Research, Lausanne, Switzerland), and Tadatsugu Taniguchi (Univer-
sity of Tokyo, Tokyo, Japan), respectively. Wild-type C57BL/6 (B6) mice
(catalog no. 000664) were purchased from the Jackson Laboratory
(Bar Harbor, ME). IFN-/R/, IRF-3/, IRF-7/, IRF-3/ 
IRF-7/, IFN-/Rf/f, CD11c-Cre, and LysM-Cre mice (15, 19, 20, 26,
48, 57, 65), as well as IFN-/Rf/f  LysM-Cre and IFN-/Rf/f 
CD11c-Cre mice, were bred and housed at Washington University, St.
Louis, MO, under specific-pathogen-free conditions (8), in accordance
with federal and university guidelines. All of these mice were fully back-
crossed to the C57BL/6 background.
Seven- to eight-week-old, sex-matched mice were orally inoculated
with 25 l of MNV diluted in phosphate-buffered saline (PBS) or mock
inoculated with 25l of PBS. Mice were sacrificed 3 days after inoculation,
and tissue and serum were harvested (10).
Virus stocks and plaque assays. A concentrated stock of MNV-
1.CW3 (69), herein referred to as MNV, was generated using RAW 264.7
cells (American Type Culture Collection [ATCC], Manassas, VA) as de-
scribed previously (10) and used in all experiments. MNV titer was deter-
mined by plaque assay (10, 76) with the following modifications: suspen-
sion-adapted RAW 264.7 cells were plated in DMEM supplemented with
10% fetal bovine serum (FBS), 100 g/ml penicillin and streptomycin
(P/S), 2 mM L-glutamine, and 10 mM N-2-hydroxyethylpiperazine-N9-
2-ethanesulfonic acid (HEPES) (pH 7.3). Cells were inoculated with
MNV and overlaid with 2 ml/well of overlay medium [MEM supple-
mented with 10% FBS, 100 g/ml P/S, 2 mM L-glutamine, and 10 mM
HEPES and containing 1% methylcellulose (viscosity, 1,500 cP) (Sigma,
St. Louis, MO)]. After 2 to 4 days of incubation at 37°C in 5% CO2, the
overlay medium was removed and plaques were visualized with a 1%
crystal violet–20% ethanol solution.
Cell culture, interferon treatment, and infection. RAW 264.7 cells
were grown as described previously (76). Suspension-adapted RAW 264.7
cells were grown at 35°C and maintained in MEM supplemented with
10% bovine serum, a 1% final concentration of nonessential amino acids,
100 g/ml P/S, 2 mM L-glutamine, 10 mM HEPES, and 0.225% (wt/vol)
sodium bicarbonate. Primary bone marrow-derived macrophages (herein
referred to as macrophages) were generated as described previously (79)
with the following modification: bone marrow cells were incubated in
culture medium for 7 days, after which adherent cells were harvested and
replated in fresh culture medium. Primary bone marrow-derived den-
dritic cells (herein referred to as dendritic cells) were generated as de-
scribed previously (36) with the following modification: bone marrow
cells were incubated in culture medium for 7 days, after which nonadher-
ent cells were harvested and replated in fresh culture medium. For in vitro
infections, macrophages and dendritic cells were plated on day 7 at a
density of 2 105 cells/well in 24-well plates or 1 106 cells/well in 6-well
plates. Macrophages and dendritic cells were either untreated or treated
with 100 U/ml of recombinant IFN-4 or recombinant IFN- 12 to 16 h
before inoculation (PBL InterferonSource, Piscataway, NJ). Macrophages
were inoculated on day 10 of in vitro culture with MNV at a multiplicity of
infection (MOI) of 0.05 (76) and either left untreated or treated with 100
U/ml of IFN-/ after inoculation. Dendritic cells were inoculated on day
7 of in vitro culture with MNV at an MOI of 0.05 (76) and either left
untreated or treated with 100 U/ml of IFN-/ after inoculation. Cells
and supernatant were harvested at 48 hours postinfection (hpi) and then
stored frozen at80°C.
Quantification of IFN-/ activity. Levels of biologically active IFN-
/ were determined using an EMCV cytopathic effect bioassay per-
formed in L929 cells as described previously (55) with the following mod-
ification: prior to the assay, serum samples were treated with citrate buffer
(40 mM citric acid, 10 ml KCl, 135 mM NaCl [pH 3.0]) for 5 min and
neutralized with medium containing 45 mM HEPES. The amount of IFN-
/ per ml of serum was calculated from a standard curve using IFN-
(PBL InterferonSource) and adjusted for the background inhibitory ac-
tivity of naïve serum (approximately 0.1 IU/ml). The inhibitory activity of
naïve serum was IFN-/ independent because it was acid labile but was
resistant to treatment with heat (56°C) and the IFN-/R-blocking anti-
body MAR1-5A3 (61).
Quantitative RT-PCR. Macrophages and dendritic cells were either
mock inoculated or inoculated with MNV at an MOI of 10 for 8 or 12 h as
described above. Total RNA was isolated and cDNA was synthesized as
described previously (23). Quantitative reverse transcription-PCR (qRT-
PCR) was performed with SYBR green (Invitrogen, Carlsbad, CA) using
primers for IFN-4 (5=-TGT GTG ATG CAG GAA CCT CCT-3= and
5=-GGT ACA CAG TGA TCC TGT GG-3=), IFN- (5=-ATA AGC AGC
TCC AGC TCC AAG-3= and 5=GTCTCATTCCACCCAGTGCTG-3=)
and 18S (5=-CGC CGC TAG AGG TGA AAT TCT-3= and 5=-CGA ACC
TCC GAC TTT CGT TCT-3=). Viral RNA transcript levels were normal-
ized to the level of transcription of 18S rRNA within each sample using the
CT method (where CT is the threshold cycle) (40).
Statistical analyses. All data were analyzed using Prism 5 software
(Graph-Pad Software, San Diego, CA). Mean values were used to calculate
fold change.
RESULTS
IFN-/ responses control MNV infection in vivo. A combina-
tion of IFN-/ and IFN- responses mediate control of MNV
infection in vivo (28, 31, 49). To further elucidate the role of IFN-
/ in control of MNV infection in vivo, we examined the specific
contribution of IFN-/ responses in preventing lethal MNV in-
fection. Consistent with previous studies (28, 31), significant le-
thality was not observed in IFN-/R/ mice inoculated with
3  104 PFU of MNV (data not shown). However, when mice
were inoculated with higher doses of MNV (3  105, 3  106, or
3 107 PFU), we observed statistically significant lethality in IFN-
/R/ mice compared to C57BL/6 mice (wild-type control)
(Fig. 1). No lethality was observed in infected wild-type control
mice at any of the tested doses of MNV. These data demonstrate a
key role for IFN-/ responses in preventing lethal MNV infec-
tion in vivo.
Since we observed lethality in IFN-/R/ mice inoculated
with 3 105 PFU of MNV (Fig. 1A), we assessed the contribution
of IFN-/ responses in restricting MNV replication in tissues
after inoculation of mice with this dose of virus. Three days after
inoculation, we observed a significant increase in MNV replica-
Thackray et al.
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tion in the livers (300,000-fold), spleen (200,000-fold), mesenteric
lymph nodes (70,000-fold), ilea (2,000-fold), and lungs (70,000-
fold) of IFN-/R/ mice compared to wild-type controls (Fig.
2). These data demonstrate that IFN-/ responses are critical for
host restriction of MNV replication in multiple tissues.
IFN-/ responses in lysozyme M- and CD11c-expressing
cells restrict MNV replication in vivo. MNV replicates in macro-
phages and dendritic cells in vivo (75, 76), and IFN-/ and IFN-
responses restrict MNV replication in these cells in vitro (13, 28,
76). To assess the role of IFN-/ responses in macrophages and
dendritic cells in restricting MNV replication in vivo, we examined
acute MNV replication in mice with floxed alleles of the IFNAR1
chain of the IFN-/R in cells expressing either lysozyme M (IFN-
/Rf/f  LysM-Cre cells; macrophages/neutrophils) or CD11c
(IFN-aBRf/fxCD11c-Cre cells; dendritic cells) (20, 30).
Three days after inoculation, we observed a significant increase
in MNV replication in the livers (900-fold), spleens (20,000-fold),
and mesenteric lymph nodes (8,000-fold) of IFN-/Rf/fLysM-
Cre mice compared to control IFN-/Rf/f mice, which carry
floxed alleles of the IFNAR1 chain of the IFN-/R (Fig. 2A to C).
We also observed a significant increase in MNV replication in the
livers (223-fold), spleens (10,000-fold), and mesenteric lymph
nodes (15,000-fold) of IFN-/Rf/fCD11c-Cre mice compared
to levels in IFN-/Rf/f controls. In contrast to the elevated titers
observed in IFN-/R/ mice, a significant increase in MNV
replication was not observed in the lungs of IFN-/Rf/f LysM-
Cre or IFN-/Rf/fCD11c-Cre mice compared to levels in IFN-
/Rf/f controls (Fig. 2E). These data demonstrate that IFN-/
responses in lysozyme M- and CD11c-expressing cells restrict
MNV replication in vivo and suggest that further analysis of the
mechanisms of IFN-/-dependent resistance to NoV should in-
clude examination of the role of macrophages and dendritic cells,
for which MNV has a tropism (75, 76).
Since we observed elevated titers in several tissues of IFN-/
Rf/f  LysM-Cre and IFN-/Rf/f  CD11c-Cre mice, we as-
sessed the contribution of IFN-/ responses in lysozyme M- and
CD11c-expressing cells in preventing lethal MNV infection. In
contrast to the lethality observed in IFN-/R/mice, no lethal-
ity was observed in IFN-/Rf/f  LysM-Cre (n	 10), IFN-/
Rf/f  CD11c-Cre (n 	 6), or IFN-/Rf/f (n 	 16) mice inoc-
ulated with 3  107 PFU (data not shown). Thus, the extent of
IFN-/R deletion in IFN-/Rf/f  LysM-Cre and IFN-/
Rf/f  CD11c-Cre mice was not sufficient to result in lethality,
potentially because of residual IFN-/ signaling due to incom-
plete deletion of the IFN-/R in specific lysozyme M or CD11c
cells or subsets (20, 30) or to a role for IFN-/ signaling in other
cell types.
IRF-3 and IRF-7 responses restrict MNV replication in vivo
but are dispensable for preventing lethal MNV infection. IRF-3
and IRF-7 are key transcription factors that regulate IFN-/ re-
sponses following virus infection (26, 57). To assess their role in
control of MNV infection in vivo, we examined acute MNV rep-
lication in mice lacking both IRF-3 and IRF-7 (IRF-3/ 
IRF-7/) compared to wild-type and IFN-/R/ mice. Three
days after inoculation, we observed a significant increase in MNV
replication in the livers (370-fold), spleens (14,000-fold), mesen-
teric lymph nodes (3,400-fold), ilea (56-fold), and lungs (200-
fold) of IRF-3/  IRF-7/ mice compared to wild-type con-
trols (Fig. 3A to E). Of note, we also observed a further increase in
MNV replication in the livers (487-fold), spleen (14-fold), mes-
enteric lymph node (13-fold), ilea (20-fold), and lungs (14-fold)
of IFN-/R/ mice compared to levels in IRF-3/ IRF-7/
mice. These data demonstrate that IRF-3 and IRF-7 function to
restrict MNV replication in vivo but also suggest that additional
factors are involved in IFN-/ responses during MNV infection
in vivo.
IRF-3 is constitutively expressed in most cell types, whereas
IRF-7 expression is induced by IFN-/ in most cell types (56,
60). Since we observed elevated MNV titers in IRF-3/ 
IRF-7/ mice, we examined acute MNV replication in IRF-3/
mice and in IRF-7/ mice to establish the relative hierarchy of
these transcription factors in the innate immune responses to
FIG 1 IFN-/ responses prevent lethal MNV infection. Wild-type (WT) and
IFN-/R/ mice were inoculated with the indicated doses of MNV, and
survival was recorded for two independent experiments of five mice each.
Statistical significance was determined using the log-rank test.
Type I Interferon Restricts MNV Replication In Vivo
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MNV. Three days after inoculation, we observed an increase in
MNV replication in the livers (20-fold), spleens (42-fold), and
mesenteric lymph nodes (60-fold) of IRF-3/ mice and in the
livers (163-fold), spleens (1,500-fold), and mesenteric lymph
nodes (105-fold) of IRF-7/ mice compared to wild-type con-
trols (Fig. 3A to C). We also observed a significant increase in
MNV replication in the ilea (4-fold) of IRF-3/ mice and in the
lungs (3-fold) of IRF-7/ mice compared to wild-type controls
(Fig. 3D and E). These data suggest that while IRF-3 and IRF-7
independently restrict MNV replication in vivo, IRF-7 is a greater
participant in innate immune responses during MNV infection.
Since we observed roles for IRF-3 and IRF-7 in restricting
MNV replication in the ilea and lungs, we examined the relative
requirements for IRF-3 and IRF-7 in restricting MNV replication
in vivo by comparing titers in IRF-3/, IRF-7/, and IRF-3/
IRF-7/ mice. We observed increased MNV replication in the
livers (8-fold), spleens (36-fold), and mesenteric lymph nodes (2-
fold) of IRF-7/ compared to IRF-3/ mice (Fig. 3A to C).
Furthermore, enhanced MNV replication was observed in the liv-
ers (19-fold), spleens (330-fold), mesenteric lymph nodes (56-
fold), ilea (13-fold), and lungs (19-fold) of IRF-3/ IRF-7/
mice compared to IRF-3/ mice and in the spleens (9-fold),
mesenteric lymph nodes (326-fold), and ilea (152-fold) of
IRF-3/  IRF-7/ mice compared to IRF-7/ mice (Fig. 3A
to E). These data are consistent with the idea that IRF-3 and IRF-7
work together to induce both unique and overlapping tissue-spe-
cific antiviral responses, as observed for other viruses (19, 58), to
restrict MNV replication in vivo.
Because elevated MNV titers were observed in IRF-3/ 
IRF-7/ mice, we evaluated whether IRF-3 and IRF-7 are re-
quired to prevent lethal MNV infection. In contrast to results
obtained with IFN-/R/ mice, no lethality was observed in
FIG 2 IFN-/ responses restrict MNV replication in vivo. WT, IFN-/R/, IFN-/Rf/f, IFN-/Rf/f  LysM-Cre, and IFN-/Rf/f  CD11c-Cre mice
were inoculated with 3 105 PFU of MNV and tissues were harvested 3 days postinfection (dpi). MLN, mesenteric lymph node. Data are the means and standard
errors of the means from at least two independent experiments of at least four mice each. The dashed line represents the limit of detection. Titers from
IFN-/R/mice were compared with those from wild-type controls; titers from IFN-/Rf/fLysM-Cre and IFN-/Rf/fCD11c-Cre mice were compared
with those from IFN-/Rf/f controls. Statistical significance was determined using the nonparametric Mann-Whitney test. ns, not significant; *, P
 0.05; **,
P
 0.01; ***, P
 0.005.
Thackray et al.
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IRF-3/ IRF-7/mice inoculated with 3 107 PFU of MNV
(n 	 10). Thus, IRF-3 and IRF-7 are dispensable for preventing
lethal MNV infection. When combined with the observation that
IRF-3/ IRF-7/mice had reduced MNV titers compared to
IFN-/R/ mice, these data suggest that IRF-3, IRF-7, and ad-
ditional factors control MNV infection in vivo through the induc-
tion of IFN-/ responses.
Since we observed decreased MNV titers and no lethality in
IRF-3/  IRF-7/ mice compared to IFN-/R/ mice, we
investigated the production of IFN-/ during MNV infection in
vivo. High levels of IFN-/were observed in IFN-/R/ mice
3 days after MNV infection, likely due to elevated virus titers and
the lack of the IFN-/R to bind and internalize IFN-/ (1, 34)
(Fig. 3F). In contrast, circulating IFN-/ was not detected in
either wild-type or IRF-3/  IRF-7/ mice despite the ele-
vated MNV titers observed in IRF-3/  IRF-7/ mice. Of
note, circulating IFN-/ was not detected in mock-inoculated
wild-type, IRF-3/  IRF-7/ and IFN-/R/ mice (data
not shown). Our inability to detect serum IFN-/ in wild-type
mice is unexpected, as IFN-/R/mice are profoundly suscep-
tible to MNV infection, and suggests that limited IFN-/ pro-
duction at the site of virus infection may be sufficient to control
MNV infection.
IRF-3 and IRF-7 restrict MNV replication in macrophages
and dendritic cells. To directly assess the role of IRF-3 and IRF-7
in restricting MNV replication, we generated primary macro-
FIG 3 IRF-3 and IRF-7 restrict MNV replication in vivo. (A to E) WT, IFN-/R/, IRF-3/ IRF-7/, IRF-3/ and IRF-7/mice were inoculated with
3  105 PFU of MNV, and tissues were harvested 3 dpi. Virus titers shown are from three independent experiments of at least three mice each. Titers were
compared with those from wild-type controls. ns, not significant; *,P
 0.05; **,P
 0.01; ***,P
 0.005. (F) WT, IRF-3/ IRF-7/, and IFN-/R/mice
were mock inoculated or inoculated with 3 105 PFU of MNV, and serum was harvested 3 dpi. Data are from two independent experiments of three mice each.
Serum concentrations were compared with those from wild-type controls. Statistical significance was determined using the Mann-Whitney test. ns, not
significant; **, P	 0.0043.
Type I Interferon Restricts MNV Replication In Vivo
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phages and dendritic cells from wild-type, IFN-/R/, and
IRF-3/ IRF-7/mice. Consistent with a prior study (76), we
observed enhanced MNV replication in IFN-/R/ macro-
phages (12-fold) and dendritic cells (4-fold) compared to wild-
type controls (Fig. 4A and B). We also observed similarly increased
MNV replication in IRF-3/ IRF-7/macrophages (19-fold)
and dendritic cells (3-fold) compared to wild-type controls (Fig.
4A and B). These data demonstrate that IRF-3 and IRF-7 restrict
MNV replication in primary macrophages and dendritic cells.
IRF-3 and IRF-7 are required for IFN-/ induction but are
dispensable for the downstream antiviral activity mediated by
IFN-/. To further elucidate the role of IRF-3 and IRF-7 during
MNV infection, we examined MNV replication in macrophages
and dendritic cells from wild-type, IFN-/R/, and IRF-3/ 
IRF-7/ mice after treatment with IFN-4 or IFN-. We elected
to examine the ability of IFN-4 to inhibit replication of MNV in
vitro, as virus infection in the mouse can induce both IFN-4 and
IFN- with immediate-early kinetics (38, 42). Treatment with
IFN-4 and IFN- significantly decreased MNV replication in
wild-type and IRF-3/  IRF-7/ macrophages and dendritic
cells compared to untreated controls but had no significant effect,
as expected, in IFN-4- and IFN--treated IFN-/R/ macro-
phages and dendritic cells compared to untreated controls (Fig.
4A and B). Thus, IRF-3 and IRF-7 are dispensable for the antiviral
activity mediated by IFN-4 or IFN- in macrophages and den-
dritic cells.
To assess whether IRF-3 or IRF-7 is important for induction of
IFN-/ in cells infected with MNV, we measured IFN-/
mRNA during MNV infection of wild-type and IRF-3/ 
IRF-7/ macrophages and dendritic cells. Notably, we observed
a significant decrease in IFN-4 (850-fold) and IFN- (3,600-
fold) mRNA induction in IRF-3/  IRF-7/ macrophages
compared to wild-type controls during MNV infection, with vir-
tually no induction of either cytokine seen in cells lacking both
IRF-3 and IRF-7 (Fig. 4C). In striking contrast, we observed a
limited decrease in IFN-4 (7-fold) and IFN- (11-fold) mRNA
induction in IRF-3/  IRF-7/ dendritic cells compared to
wild-type controls at 8 hpi with MNV, with near-wild-type levels
of induction by MNV of both cytokines in cells lacking both IRF-3
and IRF-7 at 12 hpi (Fig. 4D). These data demonstrate that IRF-3
and IRF-7 are essential for induction of IFN-/ during MNV
infection of primary macrophages and participate in IFN-/ in-
duction during MNV infection of primary dendritic cells. These
results also indicate that there is a cell type-specific role for these
transcription factors in IFN-/ induction during MNV infec-
tion.
DISCUSSION
IFN-/ likely plays an important role in the induction of antivi-
ral immune mechanisms during HuNoV infection and has been
shown to be important, when combined with IFN-, for control
of MNV replication. However, the contribution of IFN-/ re-
sponses to host defense during NoV infection, as well as the up-
stream initiators of these responses, is not well defined. Previous
studies using the MNV model system identified a requirement for
MDA-5 in IFN-/ production during MNV infection in vitro, as
well as a role for MDA-5 in restricting MNV infection both in vitro
and in vivo (46). In this report, we demonstrate an important role
for IFN-/ responses in control of MNV replication and patho-
genesis in vivo. Using mice with floxed alleles of the IFNAR1 chain
of the IFN-/R, we showed that IFN-/ responses in lysozyme
M- and CD11c-expressing cells, likely macrophages/neutrophils
and dendritic cells, restrict MNV replication in vivo. Moreover, by
analyzing cultured macrophages and dendritic cells, we demon-
strated that IRF-3 and IRF-7 are key mediators of the antiviral
immune response during MNV infection. The role for IRF-3 and
IRF-7 is prominently in the induction of IFN-/ rather than in
the induction of an antiviral state by IFN-/.
Macrophages and dendritic cells participate in IFN-/ im-
mune responses against MNV. The tropism of HuNoV is not
completely understood. The binding of NV-like particles to en-
terocytes, as well as histopathology in the intestines, of human
volunteers inoculated with NV or recombinant virus-like particles
(43, 59) suggests that HuNoV replicates in intestinal epithelial
cells. However, the detection of NV capsid antigen in mononu-
clear cells in the intestinal lamina propria of an infected person, as
well as in experimentally infected chimpanzees (5, 35), suggests
that HuNoV may also infect macrophages and/or dendritic cells in
gut lymphoid tissues.
MNV infects mononuclear cells in the intestinal lamina and
has a tropism for macrophages and dendritic cells in vitro (49, 75,
76). Furthermore, IFN-/ responses are important for restrict-
ing MNV replication in macrophages and dendritic cells in vitro
(13, 76). Our data suggest that IFN-/ responses in CD8 den-
dritic cells, which lack the IFN-/R (20), likely play a role in
restricting MNV replication in vivo. Data obtained from IFN-/
Rf/f  LysM-Cre mice is more complicated in that the IFNAR1
allele is floxed in macrophage-lineage cells, in particular resident
macrophages, and in neutrophils (20). To date, the role of neutro-
phils in NoV infection has not been explored. The lack of MNV
titers observed in the lung of IFN-/Rf/f  LysM-Cre and IFN-
/Rf/f  CD11c-Cre mice is consistent with the idea that IFN-
/ responses in additional as-yet-uncharacterized cell types may
also prevent MNV replication. Alternatively, incomplete deletion
of the IFN-/R in macrophages or neutrophils and dendritic
cells may occur in certain tissues of IFN-/Rf/f LysM-Cre and
IFN-/Rf/f  CD11c-Cre mice (20, 30). Given that IFN-/R
levels were not significantly decreased in plasmacytoid dendritic
cells in IFN-/Rf/f CD11c-Cre mice in a prior study (20), it is
interesting to speculate that plasmacytoid DC that constitutively
express IRF-7, which was critical for restriction of MNV replica-
tion in livers, spleens, and mesenteric lymph nodes, may regulate
IFN-/ responses at distal sites during MNV infection. Addi-
tional studies will be needed to elucidate the role of neutrophils,
and subsets of macrophages and dendritic cells, during NoV in-
fection.
IRF-3 and IRF-7 are key components of the transcriptional
antiviral response upon MNV infection. Our studies with pri-
mary macrophages revealed a requirement for IRF-3 and IRF-7
in the induction of IFN-4 and IFN- during MNV infection. In
addition, we demonstrated that both IFN-4 and IFN- can in-
hibit MNV replication in macrophages and dendritic cells in the
absence of IRF-3 and IRF-7. Consistent with these observations,
we observed elevated MNV titers in all tissues of IRF-3/ 
IRF-7/ mice compared to wild-type controls. We previously
showed that MDA-5 and TLR-3 are involved in IFN-/ release
during MNV infection (46). These new data, in combination with
prior findings, are consistent with a recent paradigm suggesting
that upon virus infection, cells utilize a subset of both pattern
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recognition receptors and IRF transcription factors to induce cell-
specific IFN-/ responses (reviewed in reference 45).
Although IFN-4 and IFN- mRNA induction was abolished
in IRF-3/  IRF-7/ macrophages, we observed IFN-4 and
IFN-mRNA induction in IRF-3/  IRF-7/ dendritic cells,
especially at later time points. Consistent with these observations,
despite elevated MNV titers in all tissues examined, IRF-3/ 
IRF-7/mice failed to succumb to lethal MNV infection, in con-
trast to IFN-/R/ mice, which were highly vulnerable. These
observations show that expression of the IFN-/R is more im-
portant for control of MNV infection than the combination of
IRF-3 and IRF-7. These observations are reminiscent of recent
studies that uncovered an IRF-3- and IRF-7-independent antiviral
mechanism during WNV and chikungunya infection in vivo (6,
16, 19), and they suggest that one or more transcription factors in
addition to IRF-3 and IRF-7 are involved in IFN-/ induction or
IFN-/ antiviral effects during MNV infection in vivo. To date,
these additional transcription factor(s) remain unknown; a signif-
icant decrease in IFN-4 and IFN- mRNA induction during
MNV infection was not observed in macrophages lacking IRF-1
compared to wild-type controls (L. Thackray, unpublished obser-
vations), but this may reflect compensatory effects of IRF-3 or
IRF-7. Alternatively, IRF-3/  IRF-7/ mice may be pro-
tected against lethal MNV infection by compensatory immune
mechanisms, such as enhanced IFN- production, in a manner
similar to that of murine cytomegalovirus infection, or by en-
hanced IFN- production (33, 62, 64). Future studies will be
needed to identify other transcription factors involved in initiat-
ing antiviral host responses during NoV infection.
IRF-3 and IRF-7 prevent disseminated MNV infection.
HuNoV infection is typically associated with gastrointestinal
symptoms, including nausea, vomiting, and watery diarrhea (3,
24), all consistent with the current paradigm that the gastrointes-
tinal tract is the primary site of HuNoV replication. However, the
more recent association of HuNoV infection with extraintestinal
symptoms such as benign infantile seizures and encephalopathy,
as well as the detection of HuNoV RNA in serum samples from
patients (14, 47, 50, 68), suggests that HuNoV may accumulate in
other tissues of infected patients. Of note, while HuNoV RNA was
not detected in serum of experimentally infected chimpanzees, it
was detected in the liver (5). The mechanisms that restrict HuNoV
replication to the intestine or limit the replication of virus that is
released into the lymphatic or somatic organ systems remain un-
known.
MNV replicates in the livers, spleens, mesenteric lymph nodes,
and intestines of immunocompetent mice (27, 49, 69) and thus
can spread to extraintestinal sites after peroral inoculation. Mice
lacking B or T cells, STAT-1, or the IFN-/R and IFN- receptor
(IFN-R) sustain high levels of disseminated MNV infection, in-
FIG 4 IRF-3 and IRF-7 are required for IFN-/ induction during MNV
infection but are dispensable for the antiviral activity of IFN-/. (A) Primary
bone marrow-derived macrophages (macrophages) from WT, IRF-3/ 
IRF-7/, and IFN-/R/ mice were untreated or treated with recombi-
nant IFN-4 or recombinant IFN- and inoculated with MNV (MOI of 0.05).
Titers at 48 hpi are the mean and the standard error of the mean from four
independent experiments. Titers from untreated IRF-3/  IRF-7/ and
IFN-/R/ macrophages were compared with those from wild-type con-
trols; titers from IFN-4 or IFN- treated wild-type, IRF-3/  IRF-7/,
and IFN-/R/ macrophages were compared with those from untreated
controls. Statistical significance was determined using the unpaired t test. ns,
not significant; *, P 
 0.05; **, P 
 0.01; ***, P 
 0.005. (B) Primary bone-
derived dendritic cells from WT, IRF-3/  IRF-7/, and IFN-/R/
mice were untreated or treated with recombinant IFN-4 or recombinant
IFN- and inoculated with MNV (MOI of 0.05). Virus titers at 24 hpi are
from at least three independent experiments. Titers from untreated
IRF-3/  IRF-7/ and IFN-/R/ dendritic cells were compared with
those from wild-type controls; titers from IFN-4 or IFN--treated wild-type,
IRF-3/  IRF-7/, and IFN-/R/ dendritic cells were compared
with those from untreated controls. (C) Macrophages from WT and
IRF-3/ IRF-7/mice were mock inoculated or inoculatedwith MNV (MOI
of 10). Induction of IFN-4 and IFN-mRNA levels at 12 hpi was normalized to
18S RNA levels and calculated using the CT method. Relative induction was
determined from four independent experiments and compared to induction in
wild-type controls. Statistical significance was determined using the unpaired
t test. (D) Dendritic cells from WT and IRF-3/  IRF-7/ mice were mock
inoculated or inoculated with MNV (MOI of 10). Induction of IFN-4 and IFN-
mRNA levels at 8 and 12 hpi was normalized to 18S RNA levels and calculated
using theCT method. Relative induction was determined from three indepen-
dent experiments and compared to induction in wild-type controls.
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cluding in the brain and lung (31, 49, 66). Our data show that
IRF-3 and IRF-7, as well as signaling through the IFN-/R, in-
duce an antiviral response that limits dissemination of MNV
and/or the replication of the virus in extraintestinal organs. These
effects could be due to increased MNV replication at primary sites
of replication such as the intestine, changes in the release of the
virus into the circulation, or uncontrolled MNV replication in
other organs. In this study, we observed that MNV titers in mice
lacking IRF-3 and IRF-7 or the IFN-/R increased more dramat-
ically in extraintestinal sites than in the intestine. Combined with
previous observations of high MNV titers in the intestine of mice
lacking components of both the IFN-/R and IFN-R pathways
(28, 49, 66), the data presented in this study suggest a key role for
IFN-/ responses in controlling norovirus replication at ex-
traintestinal sites and a role for additional antiviral responses,
such as those mediated by IFN-, in controlling norovirus repli-
cation in the intestine. Although the idea is speculative, impaired
IFN-/ production during HuNoV infection in a subset of indi-
viduals, such as children or immunocompromised adults, could
result in disseminated HuNoV infection and more severe disease.
IFN- limits expression of HuNoV RNA and protein expres-
sion in cells expressing an NV replicon (12), indicating that the
cytokine is important for control of both human and murine no-
rovirus replication. It is interesting to speculate that the findings
here regarding mechanisms of IFN-/ control of MNV reflect
similar antiviral mechanisms that control other NoV. Future
studies that elucidate the molecular pathways that induce IFN-
/ and initiate IFN-/ responses in specific cells and tissues
during MNV infection may identify novel targets for vaccination
or therapeutic strategies to prevent or treat NoV infection.
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